Compugen (CGEN) Corporate presentation summary

Vision and strategy

• Aims to transform patient lives by developing first-in-class therapeutics using a proprietary computational discovery platform.

• Focuses on novel immuno-oncology antibodies, leveraging computational target discovery.

• Maintains a rich pipeline with multiple assets and partnering opportunities, including collaborations with AstraZeneca and Gilead.

• Expected cash runway extends into 2027, with a $101M cash balance as of March 31, 2024.

Pipeline highlights and clinical programs

• COM701 is a potential first-in-class anti-PVRIG antibody, showing clinical benefit in tumors typically unresponsive to immunotherapy.

• COM902 is a potential best-in-class anti-TIGIT antibody, with high affinity and reduced Fc function, partnered with AstraZeneca for next-gen bispecifics.

• COM503, a first-in-class anti-IL-18BP antibody, is licensed to Gilead with up to $848M deal value and milestone payments.

• Multiple ongoing proof-of-concept studies in platinum-resistant ovarian cancer and metastatic colorectal cancer, with promising response rates and safety profiles.

Scientific rationale and differentiation

• Proprietary computational platform enables discovery of novel targets like PVRIG and TIGIT, supporting a combination approach to overcome immunotherapy resistance.

• COM701 and COM902 are designed to avoid depletion of CD8+ T cells, reducing potential risks and enhancing anti-tumor response.

• COM503 targets IL-18BP to release endogenous IL-18, enhancing T and NK cell activation selectively in the tumor microenvironment.